DZIF-10c is a fully human monoclonal neutralizing antibody that targets the receptor-binding domain of the SARS-CoV-2 spike protein and powerfully blocks the original virus as well as the B.1.1.7 variant (and, with lower potency, B.1.351). In mice, both systemic and intranasal dosing cleared infectious virus from the lungs, reduced lung pathology, and—thanks to a favorable pharmacokinetic profile—positions DZIF-10c as a promising prophylactic or therapeutic antibody that could be delivered topically via the nose.
Pharmacokinetics
parameteres estimated from [1] and dosage 40 g
References
1. Halwe, S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M., Rohde, C., Krähling, V., Gellhorn Serra, M., Kreer, C., Klüver, M., Sauerhering, L., Schmidt, J., Cai, Z., Han, F., Young, D., Yang, G., Widera, M., Koch, M., ... Becker, S. (2021). Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses, 13(8), 1498. DOI: 10.3390/v13081498 - 06/2025 Tomas Kulhanek, initial version to fit reported data
Generated at 2025-07-21T18:21:10Z
by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos
.Pharmacolibrary.Drugs.Z_Unclassified.J06B_ProbableImmunoglobulins.DZIF10c.DZIF10c_1C